If Race doesn't do a licensing agreement for AML , what would you reckon their strategy would be @IndexInvestor@johndprent
The reason I ask is because @Davisite doesn't seem to be a fan of giving away a lot of the upside and it would be hard to expect BP to put in money for a drug that is still few months away from being clinic ready.
My guess is another SPP but with options thrown in . I am happy to support another SPP depends how attractive it will be for me as well as how detailed the strategy will be.
RAC Price at posting:
94.5¢ Sentiment: None Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)